Symbols

EQ

Equillium·NASDAQ

--(--)

EQ Profile

Equillium, Inc.

A clinical-stage biotechnology company that developing novel therapeutics for severe autoimmune and inflammatory disorders

Industry

Pharmaceutical

Established Date

03/16/2017

Listing Date

10/12/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.equilliumbio.com

Security Type

Common stock

Office address

2223 Avenida de la Playa Suite 105 La Jolla CA 92037

Business

Introduction

Equillium, Inc., formerly Attenuate Biopharmaceuticals, Inc., was incorporated in Delaware on March 16, 2017. The company is a biotechnology innovator dedicated to developing novel therapies for the treatment of severe autoimmune and inflammatory diseases. Its lead drug candidate, EQ504, is a preclinical stage AhR modulator that initially targets ulcerative colitis, in addition to an oral bispecific inhibitor program in the preclinical stage for gastrointestinal indications.